Results 91 to 100 of about 747,551 (253)

Neoadjuvant chemotherapy is not necessarily applicable to patients with LN1-3 positive Luminal-B type operable breast cancer

Scientific Reports
The purpose of is to identify the necessity of neoadjuvant chemotherapy in luminal type breast cancer patients (HR-positive HER2-negative) by exploring the treatment characteristics, treatment plan, surgical choice and long-term prognosis between ...
Tiantian Tang, Cong Wang, Xin Lv, Zhigang Fan, Hanxiao Ren, Yuntao Li   +5 more
doaj   +1 more source

Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis

, 2010
Context Despite potentially curative resection of stomach cancer, 50% to 90% of patients die of disease relapse. Numerous randomized clinical trials (RCTs) have compared surgery alone with adjuvant chemotherapy, but definitive evidence is lacking ...
BURZYKOWSKI T, OBA K, PAOLETTI X, NITTI, DONATO, SAKAMOTO J, PIGNON JP, VAN CUTSEM E, ROUGIER P, SARGENT D, GLOBAL ADVANCED ADJUVANT STOMACH TUMOR RESEARCH INTERNATIONAL COLLABORATION GROUP, MICHIELS S, SASAKO M, OHASHI Y   +12 more
core   +1 more source

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong, Ximo Xu, Xiao Zhang, Chuntao Wu, Zhengjun Qiu, Beiyuan Hu, Zihao Qi, Qiang Tian, Yuqin Yang, Hanguang Dong, Fei Wu, Tuo Jin, Yan Zheng, Jiang Long   +13 more
wiley   +1 more source

Impact of timing of adjuvant chemotherapy on survival for early-stage node-negative small-cell lung cancerCentral MessagePerspective

JTCVS Open
Background: The relationship between timing of adjuvant chemotherapy and survival for early-stage, node-negative small cell lung cancer is not well defined, and no formal guidelines exist. We sought to evaluate whether increasing the time between surgery
Arian Mansur, MD, Adele J. Lee, BA, Alexandra L. Potter, BS, Jacob M. Sands, MD, Catherine B. Meador, MD, PhD, Michael Lanuti, MD, Chi-Fu Jeffrey Yang, MD   +6 more
doaj   +1 more source

Multi‐Omics Profiling of High‐Grade Serous Ovarian Cancer Reveals an Inflammation‐Related Lipid Metabolism Subtype Associated With Platinum Resistance

Advanced Science, EarlyView.
Through integrated proteomic and metabolomic profiling, Zhao et al. identified three molecular subtypes of high‐grade serous ovarian cancer. The high‐risk subtype exhibits activated arachidonic acid metabolism and cyclooxygenase‐2 overexpression. This metabolic axis promotes M2‐like macrophage infiltration, which contributes to platinum resistance ...
Yuxi Zhao, Junyi Li, Bo Zheng, Wanshan Liu, Yaru Wang, Shufeng Wang, Ying Cui, Huiqin Guo, Hongxia Wang, Ting Xiao, Kun Qian, Jing Zuo   +11 more
wiley   +1 more source

Survival benefits of postoperative adjuvant chemotherapy in adults aged ≥ 80 years with locally advanced gastric cancer: insights from a population-based study

Discover Oncology
Background and aims Postoperative adjuvant chemotherapy in older adults aged ≥ 80 years with locally advanced gastric cancer (LAGC) remains debated owing to concerns over treatment tolerance and limited data.
Fuhai Ma, Yangyang Zheng, Jian Cui, Zijian Li, Jinxin Shi, Tianming Ma, Xianglong Cao, Tao Yu, Guoju Wu, Gang Zhao, Jinghai Song, Qi An   +11 more
doaj   +1 more source

TET1 Inhibition Promotes Therapeutic Sensitivity in TP53‐Mutant GBM by Influencing Genome Fragility and Altering TAMs Biology

Advanced Science, EarlyView.
In TP53mut GBM cells, reduced P53 function is associated with increased TET1 expression. Genetic or pharmacological inhibition of TET1 correlates with genome fragility, including DNA damage, cellular senescence, telomere shortening, and reactive oxygen species accumulation, which may contribute to increased efficacy of antitumor therapy.
Zhuonan Pu, Jinqiu Liu, Yuxuan Deng, Shuyu Hao, Xiaoli Zhang, Mingxu Yang, Chao Guo, Chao Du, Yingdan Chen, Tai Sun, Nan Ji, Zhengping Zhuang, Jie Feng   +12 more
wiley   +1 more source

Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of Adjuvant Chemotherapy and Improved Long-Term Survival. [PDF]

Ann Gastroenterol Surg
ABSTRACT Background The Ideal Outcome is a composite quality indicator reflecting optimal postoperative course after pancreatic surgery. This study aimed to clarify the prognostic significance of achieving the Ideal Outcome and its influence on the initiation and completion of adjuvant chemotherapy.
Fukushima R, Araki K, Muranushi R, Hoshino K, Hagiwara K, Kawai S, Tsukagoshi M, Igarashi T, Kubo N, Shirabe K.   +9 more
europepmc   +2 more sources

Immediate Growth Control in Response to Boiling Histotripsy is Prognostic for Intratumoral Immune Activation

Advanced Science, EarlyView.
Boiling Histrotripsy (BH), a mechanical form of focused ultrasound (FUS), allows for non‐invasive and non‐ionizing tissue destruction. Utilizing a BH treatment protocol that yielded bifurcating primary tumor growth responses, we found that immediate BH‐induced tumor growth control identifies tumors with acute reductions in antigen‐presenting cells (APC)
Lydia E. Kitelinger, Matthew R. DeWitt, Carly M. Van Wagoner, Claire A. Conarroe, Charles C. Funk, Aaron B. Streit, AeRyon Kim, Richard J. Price, Timothy N. J. Bullock   +8 more
wiley   +1 more source

An integrated model of the transcriptome of HER2-positive breast cancer [PDF]

, 2013
Our goal in these analyses was to use genomic features from a test set of primary breast tumors to build an integrated transcriptome landscape model that makes relevant hypothetical predictions about the biological and/or clinical behavior of HER2 ...
Melissa Lau, High-seng Chai, David Rossell, Brian M. Necela (224867), Jeanette E. Eckel-Passow (228909), S. Keith Anderson (271824), Tang, Xiaojia, Rossell, David, Kevin J. Thompson (479037), E. Aubrey Thompson (224877), Sarah A McLaughlin, Baker, Tiffany R., Kalari, Krishna R., Necela, Brian M., Xiaojia Tang, Melissa Lau (479038), David Rossell (479046), Lau, Melissa, Derek C Radisky, Krishna R. Kalari (228899), Richard W. Joseph (479042), Sarah A. McLaughlin (479043), Camille, Stephan, Thompson, E. Aubrey, McLaughlin, Sarah A., S Keith Anderson, Saurabh Baheti, Tiffany R Baker, Jennifer M Kachergus, Jennifer M Carr, Joseph, Richard W., Asmann, Yan W., Kachergus, Jennifer M., Yan W. Asmann (210163), Zhifu Sun (60356), Derek C. Radisky (119628), Carr, Jennifer M., Richard W Joseph, Krishna R Kalari, Jennifer M. Carr (224872), Thompson, Kevin J., High-seng Chai (479044), Stephan Camille (479045), Kevin J Thompson, Poulami Barman (479041), Poulami Barman, Edith A Perez, Xiaojia Tang (53518), Saurabh Baheti (479040), Anderson, S. Keith, Barman, Poulami, Brian M Necela, Stephan Camille, Radisky, Derek C., Jennifer M. Kachergus (479039), Eckel-Passow, Jeanette E., Chai, High-seng, Perez, Edith A., Sun, Zhifu, E Aubrey Thompson, Yan W Asmann, Tiffany R. Baker (228915), Zhifu Sun, Baheti, Saurabh, Edith A. Perez (228921), Jeanette E Eckel-Passow   +65 more
core   +1 more source